BTIG has increased its price target for Abbott Laboratories (ABT, Financial) from $140 to $145, maintaining a Buy rating on the stock. The decision follows Abbott's strong performance in its first-quarter earnings.
The company is recognized for its robust quarterly results and positive developments concerning tariff offsets and manufacturing flexibility. A significant portion of Abbott's sales within the United States are derived from domestically produced goods. Management highlighted the Libre product, noting that its dual manufacturing facilities in the U.S. cater specifically to the U.S. market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $140.41 with a high estimate of $158.00 and a low estimate of $111.34. The average target implies an upside of 8.25% from the current price of $129.70. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $118.41, suggesting a downside of 8.7% from the current price of $129.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
